LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO, will present a corporate update and overview at two upcoming international healthcare conferences. Mr. Simes will discuss the LibiGel® (testosterone gel) clinical development plan and new primary research data indicating the potential size of the U.S. market for BioSante’s LibiGel in the treatment of female sexual dysfunction. Both conferences will feature pharmaceutical and biotech companies presenting to institutional investors, portfolio managers and analysts from around the world interested in these sectors.
